Phathom Pharmaceuticals to showcase VOQUEZNA at DDW 2026 with new clinical data on GERD treatment

Phathom Pharmaceuticals announced its participation in the Digestive Disease Week (DDW) 2026, highlighting VOQUEZNA (vonoprazan), a first-in-class drug for treating GERD and H. pylori infections. The company will present clinical and real-world data through presentations and posters, emphasizing its commitment to advancing gastrointestinal disease treatments. VOQUEZNA is approved for healing and maintaining erosive GERD, relieving heartburn, and treating H. pylori infections with antibiotics. Phathom aims to strengthen its position in the GI market and will make detailed data available post-event on its website.